Payment overview · 2025
General Payments
$2,374.53
73 reported records · 14 companies
Healthcare provider profile · identity verified
Alan Soroka, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WINDSOR LOCKS, CT · NPI 1720065428
Verified facts
What the public records show
CMS Open Payments records show Alan Soroka, MD received $2,374.53 in general payments during 2025 across 73 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,035.02 | 43.6% | 30 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $426.10 | 17.9% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $245.41 | 10.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $203.95 | 8.6% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $195.38 | 8.2% | 9 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.14 | 2.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.97 | 2.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.46 | 1.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.48 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.09 | 1.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.19 | 0.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.49 | 0.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.01 | 0.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.84 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,354.31 | 72 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $673.83 | 18 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $426.10 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $409.54 | 12 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $245.41 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $203.95 | 12 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $134.36 | 6 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $87.31 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $53.14 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.97 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $32.48 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
108 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
107 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 436 | 117 |
| Lisinopril | Lisinopril | 293 | 87 |
| Oxycodone Hcl | Oxycodone Hcl | 288 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 201 | 57 |
| Losartan Potassium | Losartan Potassium | 147 | 37 |
| Metformin Hcl | Metformin Hcl | 129 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 37 |
| Farxiga | Dapagliflozin Propanediol | 108 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 108 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | suppressed |
| Simvastatin | Simvastatin | 95 | 26 |
| Furosemide | Furosemide | 93 | 20 |
| Lorazepam | Lorazepam | 89 | 14 |
| Gabapentin | Gabapentin | 87 | 22 |
| Tramadol Hcl | Tramadol Hcl | 85 | 21 |
| Montelukast Sodium | Montelukast Sodium | 84 | 25 |
| Clonazepam | Clonazepam | 79 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | suppressed |
| Jardiance | Empagliflozin | 68 | 14 |
| Chlorthalidone | Chlorthalidone | 67 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 17 |
| Alprazolam | Alprazolam | 61 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 17 |
| Ezetimibe | Ezetimibe | 57 | 17 |
| Januvia | Sitagliptin Phosphate | 56 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 19 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Naproxen | Naproxen | 55 | 19 |
| Pregabalin | Pregabalin | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | suppressed |
| Mounjaro | Tirzepatide | 50 | 14 |
| Valsartan | Valsartan | 50 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 11 |
| Allopurinol | Allopurinol | 41 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | 12 |
| Amoxicillin | Amoxicillin | 40 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | suppressed |
| Eliquis | Apixaban | 38 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 14 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Indomethacin | Indomethacin | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Prazosin Hcl | Prazosin Hcl | 28 | suppressed |
| Famotidine | Famotidine | 26 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Pentoxifylline | Pentoxifylline | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Omeprazole | Omeprazole | 18 | suppressed |
| Prednisone | Prednisone | 18 | 12 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,374.53 · 73 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BEVESPI AEROSPHERE, BREZTRI, Cologuard Collection Kit, Fluad, Flucelvax, GEMTESA, JARDIANCE, Kerendia, Korlym, NEXLETOL, Ohtuvayre, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error